1364 results about "Anti neoplastic" patented technology

Provided is an antibody-drug conjugate for use in the treatment of cancer in which one or more KRAS mutants, particularly a KRAS G12V mutant, a KRAS G12D mutant, and a KRAS G12C mutant, are expressed. Also provided are a drug and a drug-linker conjugate for use in the antibody-drug conjugate.　The present inventors have produced an antibody-drug conjugate with which a heterocyclic compound represented by formula (II) and having an activity of inducing the decomposition of KRAS mutant proteins can be delivered to cancer in which EGFRs are expressed, the production being achieved by linking the compound to an anti-EGFR antibody. The present inventors have also discovered a drug-linker conjugate for use in the antibody-drug conjugate or a salt thereof. In cancer in which EGFRs are expressed, the antibody-drug conjugate induces the decomposition of one or more KRAS mutants, particularly a KRAS G12V mutant protein, a KRAS G12D mutant protein, and a KRAS G12C mutant protein, thereby inhibiting the KRAS mutants and exhibiting an anti-tumor effect.

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

The invention relates to an anti-CD3 nano antibody, an anti-CD38 antibody and a bispecific antibody containing the anti-CD3 nano antibody and the anti-CD38 antibody. According to the invention, an anti-CD3 nano antibody and an anti-CD38 monoclonal antibody are excavated and prepared, humanized design is carried out to obtain antibodies with high affinity and specificity, and different configurations of bispecific T cell conjugation antibodies targeting CD3 and CD38 are further designed, so that the CD3 and CD38 dual-specificity T cell conjugation antibodies are obtained. The antigen binding activity, the T cell-mediated tumor cell killing effect and the T cell proliferation and activation function of the antibody are systematically evaluated in vitro, and experimental results show that the T cell conjugation antibody can effectively recruit and activate T cells and has a remarkable killing effect on CD38 positive tumor cells, and it is further verified that the antibody has remarkable in-vivo anti-tumor activity and has a good application prospect. Therefore, the polypeptide has high affinity, good pharmacological characteristics and development potential.

The invention belongs to the technical field of genetic engineering and biological medicine, and particularly discloses a cascade response type nano-particle with a microenvironment remodeling function and a preparation method and application of the cascade response type nano-particle. The nanoparticle provided by the invention adopts a bionic hybrid membrane engineering strategy: an inner core is formed by loading an exosome inhibitor on a nano material, and the surface is covalently coupled with M2 type macrophage specific targeting peptide; the outer layer coats a macrophage membrane and active oxygen response type liposome composite membrane layer through a co-extrusion technology, and is loaded with a TLR agonist. Animal experiments show that after being injected through caudal vein, the nano-particles are enriched at a tumor site in a targeted manner through homing receptors such as membrane surface integrin alpha4beta1 and the like, and outer membrane cracking is triggered in a high-ROS tumor microenvironment, so that space-time controlled release of a TLR agonist and targeted phagocytosis of an exosome inhibitor by macrophages guided by a targeted peptide are realized. The anti-tumor synergistic effect is achieved through multiple regulation and control mechanisms, and an effective treatment strategy is provided for tumor immunotherapy.

The application describes the first-in-human study on using a anti-KLK2xCD3 bispecific antibody and another anti-cancer drug, in particular, in particular a taxane chemotherapy or Androgen Receptor Pathway Inhibitor (ARPI), to provide enhanced antitumor efficacy with a deeper and more durable clinical response.

The invention provides a gamma delta T cell preparation as well as a preparation method and application thereof, and belongs to the technical field of T cells. The liposome is prepared from the following raw materials in parts by weight: 15-20 parts of modified gamma delta T cell liposome, 1-3 parts of cell stimulating factors and 4-7 parts of culture medium freeze-dried powder, the modified gamma delta T cell lipidosome is prepared by embedding gamma delta T cells through lipidosome, coupling with acetylenic bond modified chitosan, and further mixing with MFAP4 protein and b4GALT1 protein. The culture medium freeze-dried powder is prepared by freeze-drying the culture medium in the engineering culture process of gamma delta T cells, and the cell stimulating factors are resveratrol and quercitrin. According to the gamma delta T cell preparation prepared by the invention, the survival ability and resistance of gamma delta T cells are improved, the anti-tumor activity of the gamma delta T cells is improved, and the gamma delta T cell preparation has relatively good antioxidant and anti-inflammatory effects, reduces the inhibition of inflammation on an immune system and has a very good treatment effect on pancreatic ductal adenocarcinoma.

The invention discloses an enantiokaurane compound with antitumor activity as well as a preparation method and application of the enantiokaurane compound. According to the present invention, chemical components of Western African plant I.trichantha tubers are deeply studied, and a variety of chromatographic separation methods such as macroporous resin, silica gel resin, medium pressure preparation-MCI column, gel normal pressure column and semi-preparative high performance liquid chromatography are combined to separate to obtain one enantiokaurane new compound Trichanthone B; experiments show that the compound obtained through separation has a good inhibition effect on an MIA PaCa-2 pancreatic cancer cell line and an A549 lung cancer cell line, and IC50 of the compound on the MIA PaCa-2 pancreatic cancer cell line reaches a nanomole level; the effect of the compound is stronger than that of positive drugs 5-fluorouracil and carboplatin, and the compound has the potential of being developed into new drugs for resisting pancreatic cancer and lung cancer.

The invention discloses an anti-tumor drug tablet stability prediction method based on multi-source data fusion, and particularly relates to the field of pharmaceutical preparation stability prediction, and the method comprises the following steps: S1, data acquisition; s2, extracting multi-dimensional characteristic parameters; s3, constructing a stability prediction reference model; s4, calculating a real-time attenuation index; s5, determining a deviation threshold range; s6, analyzing a stability deviation index; s7, dynamically updating a prediction result; according to the method, accurate prediction of content attenuation, related substance growth and disintegration time limit change indexes is realized through integration of multi-source data, construction of a stability prediction reference model, simple trend analysis not limited to a single factor, key influence factor marking, critical threshold setting and theoretical attenuation curve fitting; the accuracy and timeliness of stability prediction of antitumor drug tablets are effectively improved, and a scientific basis is provided for drug validity period evaluation and quality risk management and control.

The invention discloses a preparation method of polygonatum-sibiricum-sourced exosome-like nano-vesicles and application of the nano-vesicles in antitumor drugs, and relates to the technical field of biological medicines. The preparation method comprises the following steps: crushing fresh rhizoma polygonati slices, filtering and collecting to obtain a first filtrate; carrying out gradient centrifugation treatment on the first filtrate to obtain supernate; carrying out first membrane filtration treatment on the supernate to obtain second filtrate with the particle size of less than 450 nm; centrifuging the second filtrate to obtain a precipitate, and resuspending the precipitate with a PBS buffer solution to obtain a rhizoma polygonati exosome crude extract; and performing secondary membrane filtration treatment on the rhizoma polygonati exosome crude extract to obtain a third filtrate with the particle size of less than 220nm, thereby obtaining the rhizoma polygonati-derived exosome-like nano-vesicles. The polygonatum-sibiricum-sourced exosome-like nano-vesicle has remarkable inhibitory activity on tumors, provides a new strategy and means for tumor treatment, and has important scientific value and clinical application potential.

The invention discloses poplar and phellinus igniarius polysaccharide SVP-1 as well as a preparation method and application thereof, and belongs to the field of biological medicines. The poplar phellinus igniarius polysaccharide SVP-1 provided by the invention has remarkable anti-tumor activity, and can effectively inhibit proliferation, invasion and migration of tumor cells so as to block malignant progression of tumors. The structure is clear, the preparation method is controllable, the stability and biological activity of polysaccharide components are ensured, and a reliable basis is provided for development of antitumor drugs. When the traditional Chinese medicine composition is used together with radiotherapy and chemotherapy medicines, a synergistic effect can be achieved, the sensitivity of tumors to treatment can be improved, the toxic and side effects of radiotherapy and chemotherapy can be relieved, and the effects of reducing toxicity and increasing efficiency are achieved. According to the combined treatment strategy, the curative effect of the existing tumor therapy can be remarkably improved, meanwhile, adverse reactions are reduced, and a new optimization scheme is provided for clinical tumor treatment.

The present invention relates to a hetero (aromatic) ring-substituted cyclic diamine compound, the preparation thereof and the use thereof in the preparation of a drug for treating and / or preventing tumors. The structural formula of the compound is as shown in (I). The compound has a significant inhibitory effect on the growth of cells of tumors such as leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophageal cancer, glioma, kidney cancer, nasopharyngeal carcinoma, liver cancer, gastric cancer and pancreatic cancer. Compared with the prior art, the compound of the present invention has a broad-spectrum anti-tumor activity, has a good effect on inhibiting tumors, and has an effect of degrading PD-L1 proteins, and is thus a PD-L1 immunomodulator.

The present application relates to the technical field of small molecule drugs, in particular to a isoquinoline drug and its application in improving or treating digestive tract tumors, and aims to provide a compound, a pharmaceutical composition containing the compound and its application in treating colorectal cancer and gastric cancer, and provides a 3,13-position substituted berberine derivative, the drug itself has less toxicity and does not affect the growth of normal human cells, and has a good application prospect in the development of novel antitumor drugs, especially in the development of anti-digestive tract tumor drugs.

The invention discloses application of uncaria acidic polysaccharide URP-2 in preparation of an anti-esophageal cancer drug, and belongs to the technical field of antitumor of medicinal plant polysaccharide. According to the method, a method for extracting the uncaria total polysaccharide by boiling water and precipitating the uncaria total polysaccharide by ethanol is adopted, and a DEAE DE-52 cellulose column and sephadex column purification technology is combined, so that the separation of the uncaria acidic polysaccharide component is realized, and the uncaria acidic polysaccharide URP-2 is obtained. The uncaria acidic polysaccharide URP-2 comprises the following components in mole percent: 14.11% of arabinose, 12.64% of rhamnose, 6.48% of galactose, 5.00% of glucose and 61.77% of galacturonic acid. Experiments show that the uncaria acidic polysaccharide URP-2 has remarkable anti-esophageal cancer activity, so that a potential experimental basis and a new strategy are provided for applying the uncaria acidic polysaccharide URP-2 to clinical treatment of esophageal cancer.

The invention provides an alkaloid compound as well as a preparation method and an application thereof in tumor resistance. The alkaloid compound provided by the invention shows a remarkable cytotoxic effect on human non-small cell lung cancer cells A549, mouse lung adenocarcinoma cells Lewis, human triple negative breast cancer cells MDA-MB-231 and mouse breast cancer cells 4T1, and can be used for preparing medicines for treating breast cancer, lung cancer and the like.

The invention belongs to the technical field of medicines, and provides a novel method for overcoming multidrug resistance of tumors based on innate immune regulation. The invention relates to an application of an agonist of an innate immune STING pathway and an ENPP1 inhibitor in overcoming multidrug resistance of tumors and enhancing an anti-tumor curative effect. The STING agonist or the ENPP1 inhibitor is combined with an anti-tumor chemical drug for application, so that the effects of overcoming the multi-drug resistance of chemotherapeutic drugs and enhancing the anti-tumor curative effect are achieved. The STING agonist / or ENPP1 inhibitor has the effect of reversing multidrug resistance of tumors, and can enhance the sensitivity of cancer cells to chemotherapeutic drugs and monoclonal antibody drugs, so that the curative effect of antitumor drugs is enhanced, and the STING agonist / or ENPP1 inhibitor is expected to be developed into a novel reversal agent drug for multidrug resistance tumors. The novel anti-multidrug resistance strategy provides a new thought for drug design and cancer treatment, and has a great application prospect in clinical treatment of cancers.

The invention discloses a coumarin KRAS-G12C inhibitor as well as preparation and application of the coumarin KRAS-G12C inhibitor. The coumarin compound disclosed by the invention has a remarkable inhibition effect on non-small cell lung cancer cells (NCI-H23 and NCI-H358) with high expression of KRAS-G12C and pancreatic cancer cells (MIAPaCa-2), is particularly used for preparing medicines for treating and / or preventing non-small cell lung cancer and pancreatic cancer, and has a good prospect of development and application of antitumor medicines.

The invention discloses a naphthyridine mycin compound generated by streptomyces as well as a preparation method and application thereof, and belongs to the field of medicines. The naphthyridine mycin compound and the analogue of the naphthyridine mycin compound are prepared by fermenting, extracting, separating and purifying streptomyces lageri W307 (the preservation number of the strain is CGMCC (China General Microbiological Culture Collection Center) No.32721). The invention further discloses a preparation method of the naphthyridine mycin compound and the analogue of the naphthyridine mycin compound. The invention further provides application of the eight naphthyridine mycin compounds in preparation of anti-tumor drugs and application of the eight naphthyridine mycin compounds in preparation of antibacterial drugs, and potential anti-tumor drugs and antibacterial drugs are provided clinically.

The invention belongs to the technical field of biological medicines, and particularly relates to application of bleomycin or bleomycin analogues in preparation of an immunopotentiator. The invention also provides a pharmaceutical composition and application of the pharmaceutical composition in preparation of drugs for treating and / or preventing cancers. The pharmaceutical composition comprises bleomycin, bleomycin analogues or a combination thereof and an anti-tumor immunotherapeutic agent.

The invention relates to the technical field of antitumor drugs, in particular to a Ru (II) complex and a preparation method and application thereof, and the Ru (II) complex has a structure as shown in a formula I. The Ru (II) complex synthesized by the method disclosed by the invention not only has relatively high cytotoxicity, but also has good photodynamic antitumor activity. After the complex is illuminated, the efficiency of the complex entering cells in an active transportation mode can be accelerated, mitochondria and endoplasmic reticulum are targeted at the same time, mitochondrial membrane potential decline and endoplasmic reticulum stress are caused to form a dual organelle damage effect, immunogenic cell death is caused, the tumor microenvironment is adjusted, and the tumor cell immunogenicity is improved. The enrichment of dendritic cells (DCs) in tumor cells is realized, the chemotactic activity of effector T cells is improved, the proportion of CD4 < + > and Foxp3 < + > cell populations is reduced, and finally the anti-tumor immune response is activated. Meanwhile, the complex provided by the invention can also induce the cell to generate pan apoptosis, retard the cell cycle in the G2 / M period and enhance the effect of the complex in inhibiting tumor proliferation.

The invention discloses an anti-tumor drug delivery system based on click chemistry and a hollow covalent organic framework material as well as a preparation method and application of the anti-tumor drug delivery system, and belongs to the technical field of novel biomedical materials. The anti-tumor drug delivery system based on the click chemistry and the hollow covalent organic framework material comprises a bowl-shaped hollow covalent organic framework material carrier, and a click chemistry prodrug 1 and a click chemistry prodrug 2 which are loaded in the bowl-shaped hollow covalent organic framework material carrier, the click chemistry prodrug 1 is a compound containing an aldehyde group, and the click chemistry prodrug 2 is a compound containing an amino group. By combining the high-specificity reaction of click chemistry with the excellent drug loading performance of HCOF, accurate drug release can be realized in a tumor-specific microenvironment, the toxicity of normal cells can be remarkably reduced, the treatment effect is improved, and a wide clinical application prospect is shown.

The invention provides a cyclodextrin-based nano anti-tumor medicine preparation as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: preparing a graphene quantum dot deposition gold nanocage modified by a silane coupling agent, carrying out a Schiff base reaction on the graphene quantum dot deposition gold nanocage and aldehyde substituted-beta-cyclodextrin to prepare a composite carrier, and coating a targeted peptide-drug compound through the reaction, thereby preparing the cyclodextrin-based nano anti-tumor drug preparation. According to the cyclodextrin-based nano anti-tumor medicine preparation prepared by the invention, the anti-tumor medicine effect is obviously improved, meanwhile, the medicine resistance of the medicine can be reversed, the damage to normal tissues is reduced, the use amount of the medicine is reduced, the side effect after the medicine is used is reduced, the compliance of a patient is improved, and meanwhile, the stability and biocompatibility of the medicine can be improved; wide application prospects are realized.

Provided in the present invention are an oxamide compound having a structure as shown in formula (I), or a pharmaceutically acceptable salt, isotope derivative or solvate thereof, or a stereoisomer, geometric isomer or tautomer thereof, or a prodrug molecule or metabolite thereof, and a pharmaceutical composition thereof and the use thereof. The compound involved in the present invention can efficiently inhibit STAT6 phosphorylation, can be used for preparing drugs for preventing and treating inflammatory diseases, and can be used for preparing anti-tumor drugs.

The invention provides an engineered bacterium outer vesicle drug delivery system capable of efficiently penetrating a blood brain barrier and targeting glioblastoma as well as a preparation method and application of the engineered bacterium outer vesicle drug delivery system, and belongs to the field of drug delivery. The engineering bacteria outer vesicle drug delivery system comprises double-layer phospholipid layer vesicles BEVs, a drug delivery system and a drug delivery system, wherein the particle size of the double-layer phospholipid layer vesicles BEVs is 20 The anti-tumor drug is wrapped in the BEVs, the surface of the BEVs is modified with functional polypeptide, and the functional polypeptide is at least one of Angiopep-2 and TAT cell penetrating peptide. Animal experiments verify that the synergistic effect of the Angiopep-2 and the TAT peptide can overcome the problem of modification saturation of the Angiopep-2 peptide, and significantly improve the ability of BEVs to penetrate through BBB and target tumor tissues. Therefore, the BEVs modified by the Angiopep-2 peptide and the TAT peptide have the advantages of multi-stage targeting, high efficiency and synergy, and can effectively deliver chemotherapeutic drugs to tumor tissues.

The invention belongs to the field of bladder cancer treatment, and particularly relates to a drug delivery system based on combination of a biodegradable magnesium alloy stent and a double-J tube. The system comprises a biodegradable magnesium alloy stent and a double-J tube, the surface of the biodegradable magnesium alloy stent is modified by a calcium phosphate coating to form a fine needle-shaped micro-nano structure, and the biodegradable magnesium alloy stent loads an anti-cancer drug oridonin. The biodegradable magnesium alloy stent loaded with oridonin is accurately attached to a tumor part by means of ultrasonic guidance, and the double-J tube and the biodegradable magnesium alloy stent are combined for use. According to the invention, the loading efficiency of the hydrophobic drug is improved through the modification of the micro-nano structure of the calcium phosphate coating, and the anti-tumor effect of the magnesium degradation product is cooperated, so that the problems of high frequency, high toxicity and poor compliance of traditional bladder cancer perfusion treatment and difficulty in delivery of Ori and other natural drugs are solved, and finally, accurate, long-acting and low-toxicity treatment of bladder cancer is realized.

The invention relates to the technical field of biomedical materials, and discloses an antioxidant nano double-response drug delivery system and a preparation method and application thereof.The preparation method comprises the steps that mesoporous bioactive glass nano-particles with the particle size being 100-400 nm, the aperture being 2-10 nm and the specific surface area being 200-800 m < 2 > / g are adopted, amino functionalization is conducted on the surfaces, and the mesoporous bioactive glass nano-particles are prepared; the preparation method comprises the following steps: adsorbing a micromolecular antioxidant drug to mesoporous channels and surfaces of nanoparticles by using a rotary evaporation method, and finally grafting a pH-sensitive and ROS-responsive gated polymer by adopting an amide reaction to construct a nano drug delivery system capable of releasing the antioxidant drug in a pH-ROS dual-response manner, and the nano drug delivery system has good biocompatibility, and can be used for preparing a drug delivery system for the antioxidant drug in a pH-ROS dual-response manner. Antioxidant drugs can be released by intelligently responding to low pH and high ROS; by releasing small-molecule antioxidant drugs, free radicals are eliminated, oxidative stress is relieved, inflammatory response is inhibited, and the hydrogel has good application prospects in the fields of diabetes mellitus chronic wound healing, tissue engineering drug release, cancer treatment, tumor resistance and the like.

The invention discloses a polypeptide-nano-selenium compound and application of a composition of the polypeptide-nano-selenium compound in tumor resistance. The compound is composed of nano-selenium and polypeptide with a specific amino acid sequence Cys-Phe-Leu-Gly-Arg-Glu-Gly-Lys-Trp-Gly-Tyr-Cys, the polypeptide and selenium atoms on the surface of the nano-selenium form coordinate bonds through cysteine residues at two ends, and the problem that the nano-selenium is prone to aggregation and inactivation is effectively solved. The preparation method comprises the following steps: reducing ascorbic acid to prepare nano-selenium, and modifying the polypeptide on the surface of the nano-selenium through a coordination reaction. Experiments show that the change rate of the particle size of the nano-selenium is less than 5% after the compound is stored for 3 months, and the stability is remarkably improved; and the inhibition rate on various tumor cells after 72 hours exceeds 80%. The compound provided by the invention is simple in preparation process and high in safety, can be used as an active component to prepare antitumor drugs in various dosage forms such as tablets, injections and the like, and provides a new effective means and thought for tumor treatment.

The present invention belongs to the field of biotechnology and pharmaceutical engineering technology, and discloses a functionalized drug-loaded exosome based on milk exosomes, a preparation method thereof, and an application thereof. The functionalized drug-loaded exosomes include a carrier and a water-insoluble drug, and the water-insoluble drug is loaded inside the carrier; wherein the surface of the carrier is loaded with milk exosomes with functionalized molecules, and the functionalized molecule is any one of phosphatidylserine, a molecule capable of macrophage targeting, and a molecule or polymer that enhances the targeting and stability of milk exosomes; the water-insoluble drug is any one of an antibacterial drug, an antitumor drug, and a gene drug. The functionalized drug-loaded exosomes in the present invention can improve the gastrointestinal stability of oral administration and enhance the efficacy against bacterial pathogens; expand the application scope of milk exosomes in the fields of anti-intestinal bacterial infection and food preservation, and the exosome content in milk is very rich, which is convenient for large-scale preparation and has important application value.

The invention discloses an application of a pharmaceutical composition of erianin (ERI) and sorafenib (SOR) in preparation of an anti-liver cancer drug. The invention further discloses a pharmaceutical composition which comprises ERI and SOR, and the specific molar ratio of ERI to SOR is optimized and determined through an in-vitro experiment. The composition is developed based on multi-mode screening (network pharmacology prediction, molecular docking and molecular dynamics simulation) of STAT3 targets, and in-vitro experiments prove that the composition has synergistic anti-tumor activity and can be used for preparing anti-liver cancer drugs. The invention further discloses a development method of the ERI-SOR composition integrated with multi-mode computational simulation. Experiments prove that ERI and SOR both show a remarkable synergistic effect (combination index (CI) lt, 1) at the concentration of 0.5-16 [mu] M, CI at the optimal ratio (1: 1, 4 [mu] M + 4 [mu] M) reaches 0.617, the cell proliferation inhibition effect is remarkable compared with that of a single drug, and the excellent synergistic effect is shown.

The invention relates to the field of biological medicine, and discloses application of a GADD34 inhibitor in preparation of a medicine for enhancing CAR-T cell tumor treatment. The invention provides an innovative strategy for inhibiting CAR-T cell depletion through targeted regulation and control of an endoplasmic reticulum stress pathway to solve the problems that in an existing CAR-T therapy, the anti-tumor activity is reduced, and the solid tumor treatment effect is insufficient due to T cell depletion. Researches find that an IRE1-XBP1 pathway is used as a core signal axis of endoplasmic reticulum stress, and excessive activation of the IRE1-XBP1 pathway can drive CAR-T cell depletion related phenotypes (such as PD-1 / LAG-3 up regulation and cytokine secretion reduction). Screening experiments show that inhibiting the upstream regulatory factor GADD34 of the IRE1 not only can effectively reduce the IRE1-XBP1 signal intensity, but also can cooperatively relieve the endoplasmic reticulum stress pressure by regulating protein translation recovery, so that the CAR-T cell steady state is more comprehensively maintained. Therefore, the GADD34 inhibitor can provide a new way for enhancing CAR-T cell tumor treatment.

The invention discloses a modular tumor microenvironment response polypeptide and a preparation method and application thereof. The modular tumor microenvironment response polypeptide is composed of the following functional modules: a targeting and chemotactic module used for targeting tumor cell surface p32 protein and tumor lymphatic vessels and promoting tumor tissue penetration and enrichment; the microenvironment double-response module is used for being cut by MMP-2 / 9 enzyme and broken by high-concentration glutathione GSH in a tumor microenvironment to trigger self-assembly; the self-assembly driving module is used for exposing after the microenvironment responds to activation and driving short peptides to be self-assembled to form a nano structure; a killing module: a pro-apoptotic peptide PAD used for targeting a mitochondrial membrane and inducing tumor cell apoptosis; and the stability optimization module is used for enhancing the degradation resistance of the oligopeptide. By integrating targeted delivery, enzyme digestion response, acid-sensitive release and stabilizing structures, the problems of insufficient targeting property, inaccurate release, poor stability, diagnosis-treatment splitting and the like of the anti-tumor drug and the developing agent are solved.